Compare ResMed Inc. (RMD) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Simon Property Group Inc — how do they compare? ResMed Inc. trades at $225 (market cap $32.61B), while Simon Property Group Inc trades at $219.28 (market cap $71.03B). The key difference: Simon Property Group Inc is far larger — about 2.2× ResMed Inc.'s market cap, and Simon Property Group Inc pays the higher dividend (4.05%). Which is the better fit depends on your goals.
| RMD | SPG | |
|---|---|---|
Market Cap | $32.61B | $71.03B |
Sector | Health | Real Estate |
52-Week High | $293.73 | $236.70 |
52-Week Low | $182.82 | $169.22 |
Enterprise Value | $31.97B | $99.48B |
Dividend Yield | 1.17% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Simon Property Group (SPG) trades at $220.31, down 0.11% on the day, with a bearish technical signal as price tests support near $218. The company reported strong Q2 2026 FFO of $3.29 per share, beating estimates, and raised full-year guidance, driven by robust leasing and retailer sales growth. Financials show high profitability with a net income margin of 66.57% and ROE of 135.7%, though valuation ratios like P/S of 10.29 and P/B of 16.16 appear elevated.
Outlook remains positive with analyst consensus favoring a Buy rating and a $226.58 price target, supported by operational strength and dividend reliability. Key risks include high leverage with $24.21B in long-term debt and sensitivity to interest rates. Earnings growth and strategic acquisitions present upside, but macroeconomic headwinds could pressure retail real estate demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
